Document Detail


Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma.
MedLine Citation:
PMID:  11305415     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Interferon-alpha (IFN-alpha) has been safely given concurrently with radiation therapy (RT) in treating gliomas. As single agents, both IFN-alpha and cis-retinoic acid (CRA) have produced objective tumor regressions in patients with recurrent gliomas. In vitro, IFN-alpha2a and CRA enhance radiation therapy effects on glioblastoma cells more than either agent alone. This trial was conducted to determine the clinical effects of IFN-alpha2a and CRA when given concurrently with radiation therapy to patients with high-grade glioma. Newly diagnosed patients with high-grade glioma received IFN-alpha2a at a dosage of 3 to 6 million IU s.c. 4 times a day for 3 days per week and 1 mg/kg CRA by mouth 4 times a day for 5 days per week during the delivery of partial brain radiation therapy at 180 cGy x 33 fractions for 5 days per week for a total of 59.4 Gy during the 7-week period. Use of the antiepileptic phenytoin was prohibited after observing that the combination of IFN-alpha2a, CRA, and phenytoin was associated with a high rate of dermatologic toxicity not seen in a previous study with concurrent IFN-alpha2a and radiation therapy. Forty patients (26 men and 14 women) with a median age of 60 (range, 19 to 81 years) were enrolled between August 1996 and October 1998. Histopathologic diagnoses were glioblastoma multiforme or grade 4 anaplastic astrocytoma in 36 patients, and grade 3 anaplastic astrocytoma in 4 patients. Only 4 patients (10%) underwent a gross total resection of tumor prior to this therapy; 50% were asymptomatic when treatment was initiated. The planned 7-week course of concurrent therapy was completed by 75% of patients; 30% completed the 16-week course of IFN-alpha and CRA alone. At a median follow-up of 36 months, there were 37 deaths, with a median overall survival of 9.3 months and a 1-year survival rate of 42%. There was no improvement in survival compared with a similar group of 19 patients treated with concurrent IFN-alpha2a and radiation therapy in a previous trial. In the high-risk group of patients in the present study, concurrent treatment with IFN-alpha2a, CRA, and RT was feasible, but was not associated with a better outcome compared with a similar patient population treated with radiation therapy and IFN-alpha2a, or compared with radiation therapy alone in other trials.
Authors:
R O Dillman; W M Shea; D F Tai; K Mahdavi; N M Barth; B R Kharkar; M M Poor; C K Church; C DePriest
Related Documents :
20980335 - Targeted therapy for high-grade glioma with the tgf-β2 inhibitor trabedersen: results ...
24584365 - Correlation between grades of intraventricular hemorrhage and severity of hypoxic ische...
1564535 - The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with pcv c...
7760195 - Supratentorial-infraoccipital approach for posteromedial temporal lobe lesions.
11241245 - Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic ...
7850525 - Malignant melanoma in children.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  Neuro-oncology     Volume:  3     ISSN:  1522-8517     ISO Abbreviation:  Neuro-oncology     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-04-17     Completed Date:  2001-05-31     Revised Date:  2008-11-20    
Medline Journal Info:
Nlm Unique ID:  100887420     Medline TA:  Neuro Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  35-41     Citation Subset:  IM    
Affiliation:
Hoag Cancer Center, Newport Beach, CA 92658, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Brain Neoplasms / drug therapy*,  mortality,  radiotherapy,  surgery
Chemotherapy, Adjuvant
Combined Modality Therapy
Craniotomy
Drug Eruptions / etiology
Female
Glioblastoma / drug therapy*,  mortality,  radiotherapy,  surgery
Humans
Hypertriglyceridemia / chemically induced
Immunologic Factors / therapeutic use*
Interferon Alfa-2a / therapeutic use*
Isotretinoin / adverse effects,  therapeutic use*
Life Tables
Male
Middle Aged
Phenytoin / adverse effects,  contraindications
Radiation Injuries / etiology
Radioisotope Teletherapy* / adverse effects
Survival Analysis
Treatment Failure
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Immunologic Factors; 4759-48-2/Isotretinoin; 57-41-0/Phenytoin; 76543-88-9/Interferon Alfa-2a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adult medulloblastoma: multiagent chemotherapy.
Next Document:  A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with lept...